Therapeutic responses in asthma and COPD: Corticosteroids

Chest

Volumn 126, Issue 2 SUPPL., 2004, Pages 138S-149S

  Larj, Michael J ^a   Bleecker, Eugene R ^{a,b,c,d,e,f,g,h,i}  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b FLACSO México and UPAEP   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d GENENTECH INC   (United States)

^e GLAXOSMITHKLINE   (United States)

^f NOVARTIS   (Switzerland)

^g Pharmacia   (United States)

^h Schering   (Germany)

ⁱ Wyeth   (United States)

Author keywords

Bronchial hyperreactivity; COPD; Inhaled corticosteroids; Leukotriene receptor antagonists

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TRIAMCINOLONE ACETATE;

ASTHMA; BRONCHITIS; BRONCHUS HYPERREACTIVITY; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; GROWTH RETARDATION; HOSPITALIZATION; HUMAN; LUNG FUNCTION; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 4143093771     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.2_suppl_1.138S     Document Type: Article

References (25)

1. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program expert panel report: guidelines for diagnosis and management of asthma; update on selected topics 2002. Bethesda, MD: National Institutes of Health, 2002; workshop report publication No. 02-5075
2. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325:388-392
3. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331:700-705
4. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90:32-42
5. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155:1864-1871
6. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment: the AMPUL study group. Am J Respir Crit Care Med 1999; 159:1043-1051
7. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88:373-381
8. Panhuysen CI, Vonk JM, Koeter GH, et al. Adult patients may outgrow their asthma: a 25-year follow-up study. Am J Respir Crit Care Med 1997; 155:1267-1272
9. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054-1063
10. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487-495
11. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344:219-224
12. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-1373
13. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161:527-534
14. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-1411
15. Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med 1992; 327:1413-1419
16. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819-1823
17. 1: the Lung Health Study. JAMA 1994; 272:1497-1505
18. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948-1953
19. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1:1645-1648
20. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
21. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276
22. van der Valk P, V, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166:1358-1363
23. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456
24. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843
25. Breslin MB, Geng CD, Vedeckis WV. Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol Endocrinol 2001; 15:1381-1395